ICR-targeted therapies such as blockade of PD-1/PD-L1/CTLA4 reinvigorate antitumor immune responses and promote immune-mediated elimination of tumor cells.33 Some of these approaches have been approved for certain cancer treatments, and hundreds more are under clinical trials. Here, CTLA4 is linked to neoplasm.